Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusidic Acid Adjuvant for Complicated Cutaneous Leishmaniasis
NCT06695143Phase 3Not yet recruiting
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fusidic acid in cutaneous leishmaniasis (CL) (3 arms), sponsored by Institute of Tropical Medicine Antwerp. Primary endpoint: Improvement of index lesion at EoT at 28 days. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
fusidic acid
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06695143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06695143.